Literature DB >> 2591468

The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia.

M C Young1, N Cook, G F Read, I A Hughes.   

Abstract

The pharmacokinetics of dexamethasone, given at low dose, were studied in 13 patients with congenital adrenal hyperplasia (CAH) to ascertain whether kinetics differed in this inherited disorder of cortisol metabolism from those seen in healthy individuals. Changes in plasma dexamethasone concentration after intravenous bolus, measured using a simple novel radioimmunoassay, were well described by a two-compartment open model with first-order kinetics. Values for lambda 2: 0.206 h-1, t1/2: 3.53 h, Vc: 24.41 and f: 0.64 were similar to those previously reported for normal subjects. There were considerable interindividual differences in parameter values and Cmaxp.o. (range 22-67 nmol/l). As suppression of the hypothalamo-pituitary-adrenal axis correlates with plasma dexamethasone levels, this variability may partly explain the differing dose and dose schedule requirements necessary to achieve adequate therapeutic control in the clinical management of CAH.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591468     DOI: 10.1007/bf00609429

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Bioavailability of oral dexamethasone.

Authors:  D E Duggan; K C Yeh; N Matalia; C A Ditzler; F G McMahon
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

Review 2.  Management of congenital adrenal hyperplasia.

Authors:  I A Hughes
Journal:  Arch Dis Child       Date:  1988-11       Impact factor: 3.791

3.  Dose-dependent pharmacokinetics of dexamethasone.

Authors:  D Loew; O Schuster; E H Graul
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Standardization of symbols in clinical pharmacology.

Authors:  J K Aronson; H J Dengler; L Dettli; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Practical clinical pharmacology: drug handling and response.

Authors:  J Feely; M J Brodie
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-09

6.  Bioavailability of dexamethasone. II. Dexamethasone phosphate.

Authors:  L E Hare; K C Yeh; C A Ditzler; F G McMahon; D E Duggan
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

7.  Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia.

Authors:  P M Horrocks; D R London
Journal:  Clin Endocrinol (Oxf)       Date:  1987-12       Impact factor: 3.478

8.  The pharmacokinetics of single high doses of dexamethasone in cancer patients.

Authors:  M E Brady; G P Sartiano; S L Rosenblum; N E Zaglama; C T Bauguess
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Pharmacokinetics of dexamethasone and its phosphate ester.

Authors:  P Rohdewald; H Möllmann; J Barth; J Rehder; H Derendorf
Journal:  Biopharm Drug Dispos       Date:  1987 May-Jun       Impact factor: 1.627

10.  Dexamethasone bioavailability: implications for DST research.

Authors:  M T Lowy; H Y Meltzer
Journal:  Biol Psychiatry       Date:  1987-03       Impact factor: 13.382

View more
  5 in total

Review 1.  Antenatal treatment of a mother bearing a fetus with congenital adrenal hyperplasia.

Authors:  C G Brook
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose.

Authors:  N A Al Katheeri; I A Wasfi; M Lambert; A Saeed
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

3.  Dexamethasone therapy of congenital adrenal hyperplasia and the myth of the "growth toxic" glucocorticoid.

Authors:  Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-04-15

4.  Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia.

Authors:  Andrew Dauber; Henry A Feldman; Joseph A Majzoub
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-14

5.  Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.

Authors:  Miguel Debono; Ashwini Mallappa; Verena Gounden; Aikaterini A Nella; Robert F Harrison; Christopher A Crutchfield; Peter S Backlund; Steven J Soldin; Richard J Ross; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2015-09-04       Impact factor: 6.664

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.